Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
May M, Protzel C, Vetterlein MW, Gierth M, Noldus J, Karl A, Grimm T, Wullich B, Grimm MO, Nuhn P, et al. Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy? Results of the PROMETRICS 2011 database. Int Urol Nephrol. 2017;49(2):247–54.
Compérat E, Larré S, Roupret M, Neuzillet Y, Pignot G, Quintens H, Houéde N, Roy C, Durand X, Varinot J, et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch. 2015;466(5):589–94.
Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447–61.
van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430–42.
Kim YH, Kim WT, Jeong P, Ha YS, Kang HW, Yun SJ, Moon SK, Choi YH, Kim IY, Kim WJ. Novel combination markers for predicting survival in patients with muscle invasive bladder cancer: USP18 and DGCR2. J Korean Med Sci. 2014;29(3):351–6.
Li X, Shu K, Zhou J, Yu Q, Cui S, Liu J, Zhou R, Ding D. Preoperative plasma fibrinogen and D-dimer as prognostic biomarkers for non-muscle-invasive bladder cancer. Clin Genitourin Cancer. 2020;18(1):11-19.e11.
Kimura S, Soria F, D’Andrea D, Foerster B, Abufaraj M, Vartolomei MD, Karakiewicz PI, Mathieu R, Moschini M, Rink M, et al. Prognostic value of serum cholinesterase in non-muscle-invasive bladder cancer. Clin Genitourin Cancer. 2018;16(6):e1123–32.
Getzler I, Bahouth Z, Nativ O, Rubinstein J, Halachmi S. Preoperative neutrophil to lymphocyte ratio improves recurrence prediction of non-muscle invasive bladder cancer. BMC Urol. 2018;18(1):90.
De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta. 1957;2(1):70–4.
Bezan A, Mrsic E, Krieger D, Stojakovic T, Pummer K, Zigeuner R, Hutterer GC, Pichler M. The preoperative AST/ALT (De Ritis) ratio represents a poor prognostic factor in a cohort of patients with nonmetastatic renal cell carcinoma. J Urol. 2015;194(1):30–5.
Lee H, Lee SE, Byun SS, Kim HH, Kwak C, Hong SK. De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study. BJU Int. 2017;119(2):261–7.
Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the subcommittee for the management of lung cancer of the United Kingdom coordinating committee on cancer research. Br J Cancer. 1990;61(4):597–604.
Stocken DD, Hassan AB, Altman DG, Billingham LJ, Bramhall SR, Johnson PJ, Freemantle N. Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer. 2008;99(6):883–93.
Lindmark G, Gerdin B, Påhlman L, Bergström R, Glimelius B. Prognostic predictors in colorectal cancer. Dis Colon Rectum. 1994;37(12):1219–27.
Gorgel SN, Kose O, Koc EM, Ates E, Akin Y, Yilmaz Y. The prognostic significance of preoperatively assessed AST/ALT (De Ritis) ratio on survival in patients underwent radical cystectomy. Int Urol Nephrol. 2017;49(9):1577–83.
Ha YS, Kim SW, Chun SY, Chung JW, Choi SH, Lee JN, Kim BS, Kim HT, Yoo ES, Kwon TG, et al. Association between De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) and oncological outcomes in bladder cancer patients after radical cystectomy. BMC Urol. 2019;19(1):10.
Yuk HD, Jeong CW, Kwak C, Kim HH, Ku JH. De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase) as a significant prognostic factor in patients undergoing radical cystectomy with bladder urothelial carcinoma: a propensity score-matched study. Dis Markers. 2019;2019:6702964.
Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15(1):25–41.
Zapała P, Dybowski B, Poletajew S, Białek Ł, Niewczas A, Radziszewski P. Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer. World J Surg Oncol. 2018;16(1):6.
Botros M, Sikaris KA. The de ritis ratio: the test of time. Clin Biochem Rev. 2013;34(3):117–30.
Nishikawa M, Miyake H, Fujisawa M. De Ritis (aspartate transaminase/alanine transaminase) ratio as a significant predictor of recurrence-free survival in patients with upper urinary tract urothelial carcinoma following nephroureterectomy. Urol Oncol. 2016;34(9):417.e419-417.e415.
Cho YH, Hwang JE, Chung HS, Kim MS, Hwang EC, Jung SI, Kang TW, Kwon DD, Choi SH, Kim HT, et al. The De Ritis (aspartate transaminase/alanine transaminase) ratio as a predictor of oncological outcomes in patients after surgery for upper urinary tract urothelial carcinoma. Int Urol Nephrol. 2017;49(8):1383–90.
Warburg O. On respiratory impairment in cancer cells. Science. 1956;124(3215):269–70.
Dorward A, Sweet S, Moorehead R, Singh G. Mitochondrial contributions to cancer cell physiology: redox balance, cell cycle, and drug resistance. J Bioenerg Biomembr. 1997;29(4):385–92.
Whyard T, Waltzer WC, Waltzer D, Romanov V. Metabolic alterations in bladder cancer: applications for cancer imaging. Exp Cell Res. 2016;341(1):77–83.
Tai YS, Chen CH, Huang CY, Tai HC, Wang SM, Pu YS. Diabetes mellitus with poor glycemic control increases bladder cancer recurrence risk in patients with upper urinary tract urothelial carcinoma. Diabetes Metab Res Rev. 2015;31(3):307–14.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.